Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 18 2021 - 4:05PM
Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced the grant of an
inducement award to the newly appointed Senior Vice President and
Chief Manufacturing Officer, Tushar Misra, Ph.D. In connection with
the appointment, the Compensation Committee of the Board of
Directors of Mersana Therapeutics approved a stock option grant to
Mr. Misra as an inducement material to Mr. Misra entering into
employment with Mersana Therapeutics, in accordance with Nasdaq
Listing Rule 5635(c)(4). The stock option grant provides for the
purchase of up to 112,500 shares of Mersana Therapeutics common
stock, at a price of $11.56 per share, the closing price per share
of Mersana Therapeutics common stock on the date of grant, and
vests over four years, with 25% of the shares vesting on the first
anniversary of the Mr. Misra’s employment start date, and the
remainder vesting in equal quarterly installments over the
following three years, subject to Mr. Misra’s continued employment
with Mersana Therapeutics through such applicable vesting dates.
About Mersana
TherapeuticsMersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is
being studied in UPLIFT, a single-arm registration strategy in
patients with platinum-resistant ovarian cancer, as well as in
UPGRADE, a Phase 1 umbrella study in combination with other ovarian
cancer therapies. UpRi is also being studied in the expansion
portion of a Phase 1 proof-of-concept clinical study. XMT-1592,
Mersana’s second ADC product candidate targeting NaPi2b-expressing
tumors, was created using Mersana’s customizable and homogeneous
Dolasynthen platform and is in the dose escalation portion of a
Phase 1 proof-of-concept clinical study. The Company’s early-stage
programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as
well as XMT-2056, a STING-agonist ADC developed using the Company’s
Immunosynthen platform. In addition, multiple partners are using
Mersana’s Dolaflexin platform to advance their ADC pipelines. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Contact:
Investor & Media
ContactSarah Carmody, 617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024